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Improved weight attainment of extremely low-gestational-age
infants with bronchopulmonary dysplasia
J Madden, K Kobaly, NM Minich, M Schluchter, D Wilson-Costello and M Hack
Departments of Pediatrics and Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, OH, USA
Objective: To determine whether changes in neonatal practice and
morbidity since 2000 have improved the growth attainment of infants with
bronchopulmonary dysplasia (BPD).
Study Design: We compared the respective z-scores of the weight, length
and head circumference of extremely low-gestational-age infants (aged
<28 weeks) with BPD at birth, 40 weeks and 20 months corrected age
(CA) during two time periods, namely period I, 1996–1999 (n¼117)
and period II, 2000–2003 (n¼105), and examined the effects of
signiﬁcant changes in neonatal practice, morbidities and neurosensory
outcome on 20-month growth outcomes.
Result: During the most recent period (2000–2003), there was a
signiﬁcant increase in mean weight z-scores ( 1.60 vs  1.22) and
decrease in rates of subnormal weight (40 vs 21%), P<0.05 at 20 months
CA but not in those of length or head circumference. Signiﬁcant
predictors of the 20-month weight z-score included time period (period I
vs II), duration of ventilator dependence and 20-month neurosensory
abnormality (all P<0.05).
Conclusion: Despite an improvement in weight since 2000, poor growth
attainment remains a major problem among infants with BPD.
Journal of Perinatology (2010) 30, 103–111; doi:10.1038/jp.2009.142;
published online 1 October 2009
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Introduction
Despite advances in neonatal intensive care, bronchopulmonary
dysplasia (BPD) remains one of the leading morbidities among
extremely preterm children.
1 Long-term sequelae associated with
BPD include neurodevelopmental impairments and poor growth
attainment resulting from both growth failure during the neonatal
period and later during infancy.
2–6
We recently reported on decreased rates of neurosensory
abnormality at 20 months corrected age (CA) among extremely
low-birth-weight and gestational age children with BPD who were
born during the years 2000–2003 as compared with those born
during 1996–1999. This improvement was associated with changes
in neonatal practice and morbidity which included a decrease in
postnatal steroid therapy and decreased rates of severe cerebral
ultrasound abnormality.
7 However, it is unclear as to whether these
changes are also associated with improvements in the early
childhood growth of children with BPD. Thus, we sought to use the
data to examine whether the recent changes in neonatal
therapy and associated decrease in neonatal morbidity and
later neurosensory sequelae have been associated with
improved 20-month growth attainment of children with BPD.
We hypothesized that extremely low-gestational-age infants
(<28 weeks) with BPD born during the years 2000–2003
would have a signiﬁcant improvement in growth attainment
at 20 months CA as compared with those born during the years
1996–1999.
Methods
Population
The population included infants admitted to the neonatal intensive
care unit at Rainbow Babies and Children’s Hospital during two
4-year periods, namely 1996–1999 (period I) and 2000–2003
(period II). During periods I and II, 315 and 298 extremely
low-gestational-age infants, respectively, were admitted to the unit
of whom 14 (4%) and 11 (4%), respectively, were excluded because
of major congenital malformations. Of the remaining infants, 242
(80%) in period I and 228 (79%) in period II survived to 20
months CA, of whom 126 (52%) and 120 (53%), respectively, were
oxygen dependent at 36 weeks CA and were deﬁned as having
BPD.
8 This deﬁnition includes both moderate and severe disease
categories of BPD according to the National Institutes of Health
consensus deﬁnition.
9 One infant in period II was excluded from
the study as the infant had been transferred to another hospital
and the total duration of oxygen dependence was unknown. Four
infants in period I died after 36 weeks CA, yet before 20 months CA,
of causes related to their severe chronic lung disease. Eight infants
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lung disease, one infant had late onset necrotizing enterocolitis,
one had disseminated intravascular coagulation and the cause of
death of one infant who died after neonatal discharge was unknown.
A total of 117 (96%) of the 122 surviving infants with BPD in period
I and 105 (95%) of the 111 infants surviving in period II were
followed up until 20 months CA and had complete growth
measurements, including weight, length and head circumference.
Method of follow-up
Infants were followed up until 18–20 months CA, according to the
protocol of the follow-up program at Rainbow Babies and
Children’s Hospital. Weight, length and head circumference were
measured by a trained research assistant at 40 weeks postmenstrual
age (that is, the expected date of delivery) and at 20 months CA.
Children were weighed unclothed on a Health-O-Meter scale
(Pediatric Scale Model 322KG Health-O-Meter Professional, Alsip,
IL, USA) calibrated annually according to the manufacturer’s
recommendations. Length was measured using a Harpenden
infantometer (Holtain, Crymych, UK) with infants in a supine
position. Head circumference was measured using a
non-stretchable tape as the maximum occipito-frontal circumference.
Perinatal data were extracted from the hospital charts at the time
of discharge from the neonatal nursery. Demographic data
included maternal age, marital status, education level and race.
Birth data included birth weight, length and head circumference
and associated z-scores, gestational age, sex of the infant, delivery
method, multiple birth status, presence of chorioamnionitis and
maternal pregnancy-induced hypertension. Gestational age was
determined from the date of the mother’s last menstrual period,
and conﬁrmed with obstetric measures and ultrasound in most
cases. Perinatal therapies included antenatal and postnatal
steroid use, surfactant and indomethacin therapy, as well as
ligation of a patent ductus arteriosus. Postnatal steroid therapy
was prescribed for infants with chronic lung disease and
prolonged ventilator dependence at the discretion of the
attending neonatologist. The duration of administration of
parenteral nutrition was recorded. We participated in the
National Institute of Child Health and Human Development
Neonatal Research Multicenter Glutamine Nutrition Trial
during period II at which time the administration of intravenous
amino acids was advanced more rapidly than during period I.
10 We
do not have detailed information on the amount of nutrients each
infant received; however, during period I, the intravenous amino
acids were advanced to a maximum of 3gkg per day over the ﬁrst 2
weeks of life, whereas during period II, our revised nutritional
protocol included advancing to a maximum of 3gkg per day of
amino acids over the ﬁrst 3 days of life. However, this was not always
possible.
Neonatal morbidities recorded included patent ductus arteriosus,
conﬁrmed with echocardiography, sepsis, deﬁned as a positive
blood culture in the presence of clinical signs of infection and
necrotizing enterocolitis, according to the deﬁnition of Bell et al.
11
Duration of ventilator dependence was considered as a measure of
the severity of chronic lung disease. Periventricular hemorrhage
was categorized as grades I through IV, according to the deﬁnition
of Papile et al.
12 A severe cranial ultrasound abnormality was
deﬁned as the presence of a grade III or IV periventricular
hemorrhage, periventricular leukomalacia and/or persistent
ventriculomegaly at the time of discharge. Neurological
abnormalities were documented at 20 months CA according to the
Amiel-Tison
13 method of muscle tone assessment. Major
neurosensory abnormalities were deﬁned as cerebral palsy,
persistent hypertonia or hypotonia, shunt-dependent hydrocephalus
without neurological abnormality, blindness and/or deafness
requiring a hearing aid.
The study was approved by the Institutional Review Board of the
University Hospitals of Cleveland, and signed parental consent was
obtained for all study participants.
Statistical analysis
Growth outcomes examined included 20-month weight, length and
head circumference and their respective z-scores. A z-score is
calculated from the mean value of the reference population divided
by its s.d. Weight gestational age z-scores at birth and 40 weeks
were computed using the sex-speciﬁc standards described by
Kramer et al.
14 z-scores for length and head circumference at birth
and at 40 weeks were based on the intrauterine growth standards of
Usher and McLean.
15 For infants who were more than 43 weeks
postmenstrual age at the initial post-discharge visit, and at the
20-month visit, weight, length and head circumference z-scores
were computed on the basis of the the Center for Disease Control
and Prevention normative data, which are sex speciﬁc.
16
Subnormal z-scores were deﬁned as  2z (that is,  2 s.d.).
The variables compared between the two periods are listed in
Tables 1 and 3. The unpaired t-test or Wilcoxon rank sum test was
used to compare continuous variables, the w
2 or Fisher’s exact test
was used to compare categorical variables, and the Cochran–
Armitage trend test was used to compare distributions of ordinal
categorical variables.
17 Postnatal steroid therapy was considered as
whether the infant received steroid therapy (yes or no) and by the
number of days received, as a surrogate for dose effect.
We sought to examine the effect of the signiﬁcant (P<0.05)
changes in neonatal therapies and morbidities, that is, those that
differed signiﬁcantly between the two periods, on 20-month growth
attainment. These were entered in a stage-wise manner into a
model after adjusting for the time period (period I vs II),
sociodemographic factors (maternal education and race, sex
of the child) and signiﬁcant differences in birth data. The
signiﬁcant neonatal therapies were then entered, followed
by neonatal morbidities and ﬁnally by 20-month
neurodevelopmental outcome.
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Comparison of sociodemographic, perinatal and infant
birth data
Sociodemographic (Table 1) measures, including maternal
age, race and level of education did not differ between the
two periods (Table 1). There were no signiﬁcant differences
between periods in maternal obstetric factors or infant birth
data other than an increase in multiple births during
period II (P¼0.033). Mean gestational age, birth weight,
weight z-score and gender did not differ between the
two periods.
Twenty-month growth outcomes
During period I as compared with period II at mean CAs of 19.2
and 19.4 months, respectively, the mean 20-month body weight
was 10.00 vs 10.41kg (P¼0.049), the mean length was 79.5 vs
80.5cm (P¼0.088) and the mean head circumference was 46.8
vs 46.9cm (P¼0.634), respectively. Table 2 presents a comparison
between the two periods of mean weight, length and head
circumference z-scores at birth, 40 weeks and 20 months CA. These
are illustrated in Figure 1. At the time of birth, the z-scores were
similar. Between birth and 40 weeks, the expected term date of
delivery, there was a deceleration in neonatal growth during both
periods with a resultant decrease in the 40-week weight, length and
head circumference z-scores as compared with the respective birth
z-scores. Comparison of the 40-week growth parameters showed no
signiﬁcant differences between periods I and II. Catch-up growth
occurred between 40 weeks and 20 months during both periods.
Comparison of the body weight z-scores at 20 months showed a
signiﬁcantly higher weight z-score during period II. This increased
catch-up growth in weight during period II was also evidenced by a
decrease in the rate of subnormal weight attainment (z-score
< 2 s.d.) from 38% at 40 weeks to 21% at 20 months, whereas
during period I, the rates of subnormal weight attainment
decreased from 46% at 40 weeks to 40% at 20 months, respectively.
Twenty-month length and head circumference z-scores and their
rates of subnormal growth attainment did not differ signiﬁcantly
between the two time periods (see Table 2). In Table 2, the very low
length z-score at birth and 40 weeks in comparison with that of
weight and head circumference is noteworthy. This is possibly due
to inaccuracy in the measure of length in immature sick infants
many of whom are on ventilators.
Table 1 Maternal sociodemographic, obstetric and infant birth data
Period I (1996–1999) n¼117 Period II (2000–2003) n¼105 P-value
Maternal sociodemographic factors
Age (mean±s.d.) 27.5±6.7 27.3±7.2 0.817
Married, n (%) 54 (46) 40 (38) 0.225
Black race, n (%) 66 (56) 65 (62) 0.406
Education, n (%)
Greater than high school 57 (49) 42 (40)
Completed high school 44 (38) 39 (37) 0.074
a
Less than high school 16 (14) 24 (23)
Perinatal risk factors
Pregnancy-induced hypertension, n (%) 15 (13) 16 (15) 0.604
Chorioamnionitis n (%) 15 (13) 12 (11) 0.838
Antenatal steroid therapy, n (%) 84 (72) 87 (83) 0.050
Cesarean section, n (%) 64 (55) 55 (52) 0.729
Infant born outside hospital, n (%) 9 (8) 10 (10) 0.626
Infant birth data
Gestational age, weeks (mean±s.d.) 25.2±1.3 25.1±1.2 0.323
Birth weight, g (mean±s.d.) 767.4±153.0 750.1±143.6 0.386
Length, cm (mean±s.d.) 32.6±2.30 32.7±2.4 0.847
Head circumference, cm (mean±s.d.) 23.2±1.5 22.9±1.5 0.130
Male sex, n (%) 55 (47) 52 (50) 0.708
Multiple births, n (%) 15 (13) 25 (24) 0.033
In some instances, data were missing for one or two children.
aCochran–Armitage test.
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outcomes
A comparison of the neonatal therapies and morbidities are presented
in Table 3. Signiﬁcant changes in neonatal therapy between periods I
and II included an increase in the rates of surfactant therapy,
Indomethacin therapy and ligation of a patent ductus arteriosus. The
rates of postnatal steroid therapy and duration of this therapy for
those infants who received postnatal steroids decreased. The annual
Table 3 Comparison of neonatal morbidities and therapies
Period I (1996–1999) n¼117 Period II (2000–2003) n¼105 P-value
Neonatal therapies
Surfactant, n (%) 101 (86) 103 (98) 0.001
Indomethacin therapy, n (%)
a 65 (56) 84 (80) <0.001
Surgical ligation of patent ductus arteriosus, n (%) 31 (27) 42 (40) 0.032
Postnatal steroid therapy, n (%) 88 (75) 30 (29) <0.001
Days postnatal steroids (median, range)
b 25 (2–102) 8 (2–39) <0.001
Duration of ventilator dependence (median days, range) 36 (2–86) 40 (3–180) 0.027
Duration of oxygen dependence (median days, range)
c 105 (63–688) 100 (64–727) 0.357
Neonatal morbidity
Sepsis, n (%) 59 (50) 55 (52) 0.771
Patent ductus arteriosus, n (%) 78 (67) 78 (74) 0.215
Necrotizing enterocolitis, n (%) 6 (5) 8 (8) 0.446
Indirect hyperbilirubinemia, n (%)
d 11 (9) 12 (11) 0.621
Periventricular hemorrhage, n (%) 51 (44) 29 (28) 0.013
Periventricular leukomalacia, n (%) 10 (9) 7 (7) 0.599
Ventriculomegaly at discharge, n (%) 16 (14) 8 (8) 0.147
Severe cranial ultrasound abnormality, n (%)
e 30 (26) 14 (13) 0.022
aProphylaxis or treatment.
bFor those who received postnatal steroids.
cIncluding oxygen given after discharge in the home.
dBilirubin >10mg per 100ml.
eIncludes grades III–IV intraventricular hemorrhage, periventricular leukomalacia and/or ventriculomegaly at discharge.
Table 2 Comparison of weight, length and head circumference z-scores and rates of subnormal scores ( 2 s.d.) at birth, 40 weeks, 8 and 20 months corrected age
between period I (1996–1999) and period II (2000–2003)
Birth 40 weeks 20 months
Period I Period II P-value Period I Period II P-value Period I Period II P-value
n¼117 n¼105 n¼117 n¼105 n¼117 n¼105
Weight
z-score
a  0.18±0.7  0.20±0.7 0.829  1.84±0.9  1.69±0.9 0.204  1.60±1.5  1.22±1.3 0.041
z-score < 2 s.d. 0 0 46% 38% 0.259 40% 21% 0.002
Length
z-score
a  1.46±1.3  1.31±1.1 0.370  2.87±1.4  2.63±1.4 0.184  0.96±1.3  0.73±1.1 0.150
z-score < 2 s.d. 31% 29% 0.721 77% 66% 0.073 16% 9% 0.086
Head circumference
z-score
a  0.13±0.9  0.28±0.8 0.137  0.99±1.2  0.89±1.4 0.494  0.46±1.1  0.43±1.2 0.851
z-score < 2 s.d. 0.8% 0% 1.000 20% 24% 0.554 9% 8% 0.800
aBirth and 40 weeks
14,15 and 20 months.
16
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88, 77, 61 and 71%, respectively, whereas the rates during 2000, 2001,
2002 and 2003 were 33, 38, 33 and 4%, respectively. There were no
signiﬁcant changes between periods in the rates of sepsis, patent
ductus arteriosus, necrotizing enterocolitis, indirect
hyperbilrubinemia, duration of parenteral nutrition and duration of
overall hospitalization (Table 3). Signiﬁcant changes in neonatal
morbidity included a decrease in the rates of periventricular
hemorrhage but not in those of periventricular leukomalacia and
ventriculomegaly. The overall rate of severe cranial ultrasound
abnormality decreased signiﬁcantly during period II. The duration of
ventilator dependence increased signiﬁcantly in period II, although
the duration of oxygen dependence did not change.
At 20 months, as reported previously, there was a signiﬁcant
decrease in deafness requiring a hearing aid (9 vs 2%) and in
overall neurosensory abnormality (30 vs 16%) during period II.
7
The speciﬁc rates of cerebral palsy and blindness did not change
signiﬁcantly.
Multivariable analysis of correlates of growth at 20 months CA
After adjusting for the time period (period I vs II) and
sociodemographic factors (maternal education as well as race and
sex of the child), variables that changed signiﬁcantly between the
time periods were then entered in the multiple stepwise regression
analysis in a stage-wise manner. These included multiple birth
status in stage I. Signiﬁcant neonatal therapeutic changes entered
in the second stage included surfactant, indomethacin and
postnatal steroid therapy, as well as ligation of a patent ductus
arteriosus. Signiﬁcant changes in neonatal morbidity entered in
stage III included severe cranial ultrasound abnormality and the
duration of ventilator dependence, which was considered as a
measure of severity of chronic lung disease. The presence of
neurosensory abnormality at 20 months was entered in stage IV
(Table 4). The results showed that the factors found to have an
independent effect on 20-month weight included the time period of
birth (period I vs II), longer duration of ventilator dependence and
the presence of neurosensory abnormality at 20 months CA. Severe
cranial ultrasound abnormality predicted 20-month weight before
entering neurosensory abnormality in the stepwise regression
analysis, but was not signiﬁcant in the ﬁnal analysis. Stepwise
logistic regression analysis to examine the correlates of subnormal
weight (< 2 s.d.) showed similar results (see Table 5). The fact
that the time period that is, period I vs II) remained signiﬁcant
even after controlling for sociodemographic factors and identiﬁed
neonatal therapeutic and morbidity factors that changed
signiﬁcantly between the two periods indicates that other
unidentiﬁed factors contributed to the improvement in weight at
20 months.
Signiﬁcant correlates of the 20-month length and head
circumference z-scores were similar to those of the 20-month
weight, with the exception that the time period of birth was not
predictive and that male sex was predictive of the length z-score
(data not shown).
Discussion
We sought to examine whether changes in neonatal practice,
morbidity and associated neurodevelopmental outcomes since 2000
were associated with 20-month growth attainment of infants with
BPD born at <28 weeks gestation. Results showed a signiﬁcant
increase in weight attainment z-scores at 20 months during period
II but not in those of length or head circumference. Factors
signiﬁcantly associated with 20-month weight that had changed
signiﬁcantly between the time periods included the period of birth,
with the most recent period having a positive effect, and the
duration of ventilator dependence and the presence of neurosensory
impairment both of which exerted a negative effect on 20-month
Figure 1 Comparison between period I (1996–1999) and period II
(2000–2003) of the mean z-scores of weight, length and head circumference at
birth, 40 weeks corrected age (the expected date of delivery) and 20 months
corrected age.
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signiﬁcant in the multivariable model that controlled for duration
of ventilator dependence and neurosensory impairment, indicating
that changes in these factors did not completely explain the
improvement in 20-month weight between time periods.
The increase in 20-month growth during the most recent period
which extended from the year 2000 to 2003 is possibly related to
improvements in neonatal and postdischarge nutrition, as well as
to other unidentiﬁed factors and probably contribute to the fact
that the time period was a signiﬁcant factor in multivariable
analyses. Although we have no data in this regard, it is likely that a
more aggressive approach to parenteral nutrition and early oral
intake, as well as increased caloric post discharge formulae
instituted during the most recent years in our unit may have
contributed to the improvement in 20-month weight z-scores. This
occurred despite the negative effects of the increased duration of
ventilator dependence and of neurosensory impairment on growth.
Prolonged duration of mechanical ventilation has been associated
with poor growth in very-low-birth-weight populations.
4 We
speculate that the longer duration of ventilator dependence,
indicating more severe lung disease, is most likely due to the
decreased use of postnatal steroids during period II, which was
based on the evidence obtained from randomized controlled trials
of increased rates of cerebral palsy associated with its use.
18 The
negative effects of postnatal steroid therapy on growth have been
well documented.
19,20,23 However, in our population, postnatal
steroid therapy did not exert a signiﬁcant effect on growth at 20
months after adjusting for other confounding factors. We speculate
that the potential beneﬁcial effects on growth of the decreased
postnatal steroid use that occurred during period II were likely
offset by the concomitant increase in duration of ventilation
dependence, which also occurred during this time and was
associated with growth failure in our population. We similarly
found that although the rates of 20-month neurosensory
impairment decreased from 31 to 16% during period II and might
have contributed to the improvement in weight at 20 months, their
presence continued to exert a negative effect on growth outcomes.
Poor growth attainment in children with neurological abnormality
has been well documented and may be due to both nutritional
factors related to oral feeding impairments and non-nutritional
factors.
21–23
To our knowledge, this is the ﬁrst report of growth outcomes of
infants with BPD born since 2000. Our results indicate that
neonatal growth failure remains a major problem among infants
Table 4 Results of stage-wise regression analysis predictors of weight z-scores at 20 months corrected age
Variable Stage I Stage II Stage III Stage IV
B (95% CI) B (95% CI) B (95% CI) B (95% CI)
Time period (I vs II) 0.35 ( 0.02,0.72) 0.32 ( 0.11,0.76) 0.48 (0.04,0.93)
* 0.45 (0.01,0.89)
*
Sociodemographic status
Maternal education <high school 0.26 ( 0.23,0.75) 0.31 ( 0.18,0.80) 0.22 ( 0.26,0.70) 0.22 ( 0.26,0.69)
Race 0.11 ( 0.27,0.49) 0.12 ( 0.26,0.50) 0.18 ( 0.19,0.56) 0.20 ( 0.17,0.57)
Sex of child  0.12 ( 0.48,0.25)  0.12 ( 0.48,0.25)  0.12 ( 0.48,0.24)  0.10 ( 0.46,0.25)
Multiple birth  0.02 ( 0.51,0.47)  0.10 ( 0.51,0.49)  0.14 ( 0.63,0.35)  0.10 ( 0.59,0.38)
Neonatal therapy
Surfactant  0.27 ( 0.97,0.43)  0.22 ( 0.90,0.46)  0.27 ( 0.94,0.40)
Postnatal steroids  0.28 ( 0.70,0.14) 0.02 ( 0.42,0.45) 0.09 ( 0.35,0.52)
Indomethacin  0.32 ( 0.75,0.11)  0.29 ( 0.71,0.14)  0.26 ( 0.68,0.15)
PDA ligation 0.04 ( 0.38,0.45) 0.14 ( 0.26,0.54) 0.17 ( 0.23,0.57)
Neonatal morbidity
Severity of lung disease
a  0.01 ( 0.02, 0.003)**  0.01 ( 0.02, 0.002)
*
Severely abnormal ultrasound
b  0.60 ( 1.06, 0.13)
*  0.37 ( 0.86,0.13)
Neurosensory outcome
Neurosensory abnormality  0.55 ( 1.01, 0.08)
*
R
2 0.03 0.06 0.12 0.14
Abbreviations: B, unstandardized coefﬁcient (95% CI); 95% CI, 95% conﬁdence interval; PDA, patent ductus arteriosus.
aDays on ventilator
bIncludes grades III–IV hemorrhage, periventricular leukomalacia and ventricular dilatation at discharge.
*P<0.05, **P<0.001.
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between term gestation (40 weeks CA) and the second year of life,
extremely preterm infants with BPD remain deﬁcient in all growth
parameters at 20 months. Despite the increase in weight
attainment since the year 2000, 20% of infants in the BPD
population remain subnormal in weight, 9% in length and 8%
subnormal in head circumference at 20 months CA. Newer
ventilation strategies in the delivery room may contribute to a
decrease in BPD rates, but may not improve the growth of those
who do develop BPD. The strengths of our study include the
relatively large inborn patient population and high rates of follow-
up. We examined the growth outcomes by gestational age rather
than by birth weight, thus eliminating the confounding effects of
the inclusion of small-gestational-age infants of >28 weeks
gestation.
24 The limitation of our study is the lack of detailed
information on both neonatal and post-discharge nutrition, as well
as the lack of information on other factors that may affect growth.
There have been very few studies speciﬁcally regarding the later
growth of extremely preterm infants with BPD. Ehrenkranz et al.
reported that between 1995 and 1999, infants with moderate BPD
(oxygen dependence >28 days and a requirement of <30% oxygen
at 36 weeks postmenstrual age), the rates of subnormal weight,
length and head circumference (<10th percentile) at 18–22
months CA were 55, 38 and 27%, respectively. Among infants with
severe BPD (oxygen dependence >28 days and requiring X30%
oxygen and/or positive pressure ventilation at 36 weeks
postmenstrual age), the corresponding rates were 63, 46 and 39%,
respectively.
9 Huysman et al.
25 compared the growth and body
composition of infants with BPD to healthy term infants during the
ﬁrst year of life, and reported that the mean fat-free mass and total
body fat was signiﬁcantly lower in infants with BPD at both
6 weeks and 12 months CA.
In general, studies of the postnatal growth of extremely low-
birth-weight (<1kg) infants born in the 1990s report that the
majority, even those without BPD, develop growth failure in the
neonatal period. This often persists into early childhood and
later.
2,5,6,26–28 Neonatal correlates of growth failure in very-low-
birth-weight (<1.5kg) and extremely low-birth-weight infants
included necrotizing enterocolitis, late-onset sepsis, postnatal
steroid therapy, neurodevelopmental disability, BPD and feeding
problems.
2,29 BPD was the main factor associated with growth
failure between 40 weeks and 4 months CA in a cohort of very-low-
birth-weight infants examined by Sices et al.
30 There are many
speciﬁc reasons for the growth failure of infants with BPD.
Neonatal complications such as repeated episodes of infection
during prolonged neonatal hospitalization may be associated with
Table 5 Predictors of subnormal weight (<–2 s.d.) at 20 months corrected age, results of stepwise logistic regression analysis
Variable Stage I Stage II Stage II Stage IV
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Time period (I vs II) 0.39 (0.21,0.72)** 0.34 (0.17,0.71)** 0.26 (0.12,0.56)** 0.26 (0.12,0.58)**
Sociodemographic status
Maternal education <high school 0.86 (0.38,1.96) 0.81 (0.35,1.88) 0.96 (0.41,2.26) 0.97 (0.40,2.31)
Race 0.87 (0.48,1.60) 0.83 (0.45,1.55) 0.75 (0.39,1.42) 0.71 (0.37,1.37)
Sex of child 1.39 (0.77,2.50) 1.41 (0.77,2.57) 1.44 (0.78,2.69) 1.43 (0.76,2.71)
Multiple birth 1.21 (0.56,2.62) 1.17 (0.52,2.63) 1.42 (0.61,3.30) 1.32 (0.56,3.12)
Neonatal therapy
Surfactant 1.97 (0.59,6.64) 2.02 (0.58,7.12) 2.40 (0.65,8.83)
Postnatal steroids 1.17 (0.59,2.33) 0.77 (0.36,1.65) 0.65 (0.30,1.43)
Indomethacin 1.95 (0.95,3.98) 1.94 (0.93,4.05) 1.85 (0.88,3.90)
PDA ligation 0.78 (0.40,1.53) 0.66 (0.32,1.33) 0.60 (0.29,1.24)
Neonatal morbidity
Severity of lung disease
a 1.02 (1.00,1.03)* 1.01 (1.00,1.03)*
Severely abnormal ultrasound
b 2.49 (1.17,5.30)* 1.56 (0.68,3.61)
Neurosensory outcome 3.03 (1.39,6.62)**
Abbreviations: 95% C.I., 95% conﬁdence interval; OR, odds ratio; PDA, patent ductus arteriosus.
aDays on ventilator.
bIncludes grades III–IV hemorrhage, periventricular leukomalacia and ventricular dilatation at discharge.
*P<0.05, **P<0.001.
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Journal of Perinatologypoor neonatal nutrition. Chronic hypoxia may result from frequent
episodes of oxygen desaturation both at rest and during feeds;
31–33
increased energy expenditure associated with the work of breathing
may also affect growth.
34 Feeding problems have also been
described in infants with BPD and include swallowing dysfunction,
oral aversion and gastroesophageal reﬂux, which may contribute to
poor nutrition and associated growth failure.
2,35–38
In conclusion, despite the improvement in 20-month weight since
2000, our results indicate that growth failure remains a major
problem among infants who develop BPD. To improve growth
outcomes in such infants, there is a need for strategies that prevent
the severity of BPD and decrease associated neonatal morbidities and
later neurodevelopmental impairment. Furthermore, neonatal and
post-discharge nutrition needs to be optimized together with early
recognition and management of feeding problems.
39,40
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